NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on Thursday, 10th August, 2023 to disseminate Financial Results of the Company for the quarter ended on 30th June, 2023 NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30Th June, 2023 And To Consider Interim Dividend For The Financial Year 2023-24, If Any
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 ,inter alia, to consider and approve Unaudited Financial Results for the quarter ended 30th June, 2023 and to consider interim dividend for the Financial Year 2023-24, if any. Janssen sues Natco Pharma overerdafitinib generic
Janssen Biotech markets erdafitinib tablets in the US under the brand Balversa NATCO Pharma's shares rise 2% on ANDA filing
The filing may grant NATCO 180 days of marketing exclusivity upon launch NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco files generic Erdafitinib Tablets in USA
Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang
Net Sales are expected to increase by 35.1 percent Y-o-Y (up 33.1 percent Q-o-Q) to Rs 1,195.4 crore, according to Nirmal Bang. NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances - Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ending June 30, 2023 NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni & Others